Serum pepsinogen level, atrophic gastritis and the risk of incident pancreatic cancer-A prospective cohort study

Cancer Epidemiology

Volumn 33, Issue 5, 2009, Pages 368-373

  Laiyemo, Adeyinka O ^a   Kamangar, Farin ^a,b   Marcus, Pamela M ^a   Taylor, Philip R ^a   Virtamo, Jarmo ^c   Albanes, Demetrius ^a   Stolzenberg Solomon, Rachael Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MORGAN STATE UNIVERSITY   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Atrophic gastritis; Pancreatic cancer; Serum pepsinogen

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; PEPSINOGEN;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GASTROSCOPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; COHORT STUDIES; GASTRITIS, ATROPHIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPSINOGEN A; PRECANCEROUS CONDITIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 70649109930     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.09.001     Document Type: Article

References (26)

1. Lowenfels A.B., and Maisonneuve P. Epidemiologic and etiologic factors of pancreatic cancer. Hematol Oncol Clin North Am 16 1 (2002) 1-16
2. Hart A.R., Kennedy H., and Harvey I. Pancreatic cancer: a review of the evidence on causation. Clin Gastroenterol Hepatol 6 3 (2008) 275-282
3. Sessa F., Bonato M., Frigerio B., Capella C., Solcia E., Prat M., et al. Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells. Gastroenterology 98 (1990) 1655-1665
4. Luo J., Nordenvall C., Nyren O., Adami H.O., Permert J., and Ye W. The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. Int J Cancer 120 (2007) 368-372
5. Mack T.M., Yu M.C., Hanisch R., and Henderson B.E. Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 76 (1986) 49-60
6. Tersmette A.C., Offerhaus G.J., Giardiello F.M., Tersmette K.W., Vandenbroucke J.P., and Tytgat G.N. Occurrence of non-gastric cancer in the digestive tract after remote partial gastrectomy: analysis of an Amsterdam cohort. Int J Cancer 46 (1990) 792-795
7. Ross A.H., Smith M.A., Anderson J.R., and Small W.P. Late mortality after surgery for peptic ulcer. N Engl J Med 307 (1982) 519-522
8. Stolzenberg-Solomon R.Z., Blaser M.J., Limburg P.J., Perez-Perez G., Taylor P.R., Virtamo J., et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 93 (2001) 937-941
9. Raderer M., Wrba F., Kornek G., Maca T., Koller D.Y., Weinlaender G., et al. Association between Helicobacter pylori infection and pancreatic cancer. Oncology 55 (1998) 16-19
10. Nilsson H., Stenram U., Ihse I., and Wadström T. Re: Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 94 (2002) 632-633
11. Nilsson H.O., Stenram U., Ihse I., and Wadstrom T. Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients. World J Gastroenterol 12 (2006) 3038-3043
12. Truan N., Vizoso F., Fresno M.F., Fernández R., Quintela I., Alexandre E., et al. Expression and clinical significance of pepsinogen C in resectable pancreatic cancer. Int J Biol Markers 16 (2001) 31-36
13. Smith J.P., Fantaskey A.P., Liu G., and Zagon I.S. Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 268 (1995) 135-141
14. Kuipers E.J. Proton pump inhibitors and gastric neoplasia. Gut 55 9 (2006) 1217-1221
15. El-Zimaity H. Gastritis and gastric atrophy. Curr Opin Gastroenterol 24 6 (2008) 682-686
16. de Vries A.C., and Kuipers E.J. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter 12 Suppl. 2 (2007) 22-31
17. Risch H.A. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 95 (2003) 948-960
18. ATBC Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study. Ann Epidemiol 4 (1994) 1-10
19. Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 (1994) 1029-1035
20. Varis K., Taylor P.R., Sipponen P., Samloff I.M., Heinonen O.P., Albanes D., et al. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and betacarotene. Scand J Gastroenterol 33 (1998) 294-300
21. Varis K., Sipponen P., Laxén F., Samloff I.M., Huttunen J.K., Taylor P.R., et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 35 (2000) 950-956
22. Samloff I.M. Pepsinogens I and II: purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology 82 (1982) 26-33
23. Price A.B. The Sydney system: histological division. J Gastroenterol Hepatol 6 (1991) 209-222
24. Korhonen P., Malila N., Pukkala E., Teppo L., Albanes D., and Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort: accuracy and delay. Acta Oncol 41 (2002) 381-388
25. de Martel C., Llosa A.E., Friedmana G.D., Vogelman J.H., Orentreich N., Stolzenberg-Solomon R.Z., et al. Helicobacter pylori Infection and Development of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev 17 (2008) 1188-1194
26. Varis K., Kekki M., Härkönen M., Sipponen P., and Samloff I.M. Serum pepsinogen I and serum gastrin in screening of atrophic pangastritis with high risk of gastric cancer. Scand J Gastroenterol Suppl 186 (1991) 117-123